Fusion backs heart research

Have your say

University spin-out funding specialist Fusion IP is backing researchers from Sheffield University who are developing a cure for a disease that causes heart failure.

Sheffield-based Fusion has backed the creation of PH Therapeutics, which has been set up to commercialise the results of research by Dr Allan Lawrie from the University’s Department of Cardiovascular Science.

The company aims to develop biological treatments for a rare disease called Pulmonary Arterial Hypertension – or PAH - which results from the thickening of the walls in arteries that take blood from the heart to the lungs.

PAH makes it harder for blood to flow through the arteries, resulting in high blood pressure, which puts a strain on the heart that can lead to difficulty in breathing and heart failure.

The disease affects around two in 10,000 people in the European Union and PH Theraputics is developing ways of targeting molecules thought to be responsible for cell wall thickening to control, and, more importantly, reverse the effects of the disease.

Fusion IP’s Peter Grant said: “PH Therapeutics is another Life-Sciences spin-out derived from the world-class research at the University.”